The Life Raft Group is committed to enhancing the survival and quality of life for people living with Gastrointestinal Stromal Tumor (GIST), and other rare diseases, through patient-powered research, education and empowerment, and global advocacy efforts.
Other Programs Supported by The Life Raft Group:
PATIENT
Leverage patient perspective to drive innovative solutions in cancer research.
POWERED
Educate and empower patients to take a larger role in their care.
SCIENCE
Accelerate research outcomes through collaborative efforts.
FOR LIFE
Increase access to effective treatments worldwide.
Real World Evidence In Action
Traditional models for cancer research have resulted in many breakthrough treatments for patients, but it is not enough. The LRG’s approach to GIST research through real world evidence, relies on timely, accurate data from the patient’s perspective, with patient survival as the primary objective.
RECENT LRG DATA
Did you know that GIST is actually a family of cancers? Learn more about the science of GIST.
Update your Patient Registry Info.
Join The Life Raft Group.
Current GIST Clinical Trials.
Search the GIST Specialist Database.
Dr. Monica Anderson
Diagnosed in 2012 with Adult GIST.
Bella Rocco
Diagnosed in 2009 with Pediatric
(SDH-deficient) GIST.
HELP US SAVE LIVES
The Life Raft Group is a community and it is up to all of us to make a difference. There are many ways to help. We always need patient tissue and data in our GIST patient registry. Volunteering your time or making a monetary donation also helps us drive research forward and save lives.
News
GIST Do It: All Year Long
GIST DO IT is an amazing way to educate the medical community and the general public about GIST. We would like to take it to the next level and encourage everyone to “GIST DO IT All Year Long.”
LRG Assisted in CAP Guidelines Modifications with a Diagnostic Algorithm
The LRG, in collaboration with the Pediatric & SDH-Deficient GIST Consortium and key opinion leaders among the GIST pathology community (with Dr. Brian Rubin taking the lead), played a significant role in changing CAP Guidelines. CAP Guidelines are protocols for pathologists to instruct them on the process of diagnosing a disease based on tumor tissue samples.
Patient of the Month for August: Guy Jones
Each member has a unique story, but all reflect the intrinsic courage of one facing the challenge of GIST. Guy Jones shares his story.
Rozlytrek™ (entrectinib) by Approved by FDA
The FDA granted the approval of Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC), [...]
Deciphera Releases Positive Trial Results for Ripretinib
Deciphera Pharmaceuticals has released positive results from their INVICTUS Phase 3 Clinical Study of Ripretinib in patients with GIST. They have [...]
Treatment Responses in SDH-deficient GIST – LRG Science
The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
LRG Releases Annual Report for 2018
In 2018, The Life Raft Group continued its dedication to patients with GIST, working diligently to enhance survival and quality of [...]
Blueprint Medicines Announces Next Step for Avaprinitib
Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and [...]
Keep up with the latest news, events, and opportunities to help.
To contact The Life Raft Group, please call 973-837-9092
PARTNERS & AFFILIATIONS
